ADG126

Phase 2Small molecule

Sanofi

ADG126 is one of 114 small molecule programs targeting Liver Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

113

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Solid TumorRecruiting

Advanced Liver CancersRecruiting

Liver CancerPhase 1/Phase 2

Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

Solid TumorPreclinical

Recruiting

Advanced Liver CancersPreclinical

Recruiting

Competition

Competitive Landscape

949 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

ADG126

Sanofi

Phase 2

1 2

Eylea

Regeneron

Preclinical

5 3

Emend IV

PORTRAZZA

Gas-X

PPortuguese Oncology Institute, Coimbra

Preclinical

1 6

Ketalar

AAultman Health Foundation

Preclinical

1 7

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 8

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Advanced/metastatic Solid Tumors

NCT05405595

Q3 2027

PreclinicalRecruiting

Advanced Liver Cancers

NCT04524871

Q4 2027

Phase 2Recruiting

Colorectal Cancer

NCT06846268

Q2 2028

PreclinicalRecruiting

Solid Tumor

NCT05584670

Clinical

Trials by Indication[1]

Advanced/Metastatic Solid Tumors1 trial

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Recruiting·AAdagene Inc·Phase 1/2·NCT05405595·186 enrolled

Colorectal Cancer1 trial

Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer

Recruiting·NNational University Hospital, Singapore·Phase 2·NCT06846268·20 enrolled

Solid Tumor1 trial

A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Solid Tumors

Recruiting· Sanofi logo

Sanofi·Preclinical·NCT05584670·542 enrolled

Advanced Liver Cancers1 trial

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Recruiting· Roche logo

Roche·Preclinical·NCT04524871·518 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ADG126. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ADG126 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ADG126. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Sanofi

ADG126

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q4 2027

Q2 2028

Trials by Indication[1]

Advanced/Metastatic Solid Tumors1 trial

Colorectal Cancer1 trial

Solid Tumor1 trial

Advanced Liver Cancers1 trial

References

Drug Info

Quick Facts

Related News